Literature DB >> 9331147

Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett's esophagus.

R Fass1, J M Yalam, L Camargo, C Johnson, H S Garewal, R E Sampliner.   

Abstract

When compared to patients with erosive esophagitis, patients with Barrett's esophagus have demonstrated reduced chemo- and mechanoreceptor sensitivity to acid infusion and balloon distension, respectively. However, anecdotal clinical experience suggested an increase in symptom perception in patients after successful elimination of Barrett's epithelium, using multipolar electrocoagulation (MPEC) and high-dose proton pump inhibitor (PPI). To determine perception thresholds to acid infusion, we evaluated eight consecutive patients after a series of MPEC treatments resulted in complete elimination of Barrett's mucosa and compared them to 10 age-matched patients with nonreversed Barrett's esophagus and 10 patients with symptomatic, endoscopy-documented erosive esophagitis (Hetzel-Dent grade 2 or greater). Chemosensitivity was determined by a modified acid perfusion test, where acid perception thresholds were quantified by the lag time to initial typical symptom perception, sensory intensity rating, and an acid perfusion sensory score (APSS). While patients after successful elimination of Barrett's esophagus had similar sensory intensity ratings and APSS as patients with erosive esophagitis, the lag times differed significantly between the groups, and both groups had significantly higher sensory intensity ratings and APSS than patients with nonreversed Barrett's esophagus. In conclusion, patients after complete reversal of Barrett's mucosa are unexpectedly as sensitive to acid as symptomatic patients with erosive esophagitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331147     DOI: 10.1023/a:1018850824287

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease.

Authors:  J L Smith; A R Opekun; E Larkai; D Y Graham
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

2.  Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus.

Authors:  M A Laukka; K K Wang
Journal:  Gastrointest Endosc       Date:  1995-07       Impact factor: 9.427

3.  Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus.

Authors:  B Overholt; M Panjehpour; E Tefftellar; M Rose
Journal:  Gastrointest Endosc       Date:  1993 Jan-Feb       Impact factor: 9.427

4.  Regression of Barrett's esophagus by laser ablation in an anacid environment.

Authors:  R E Sampliner; L J Hixson; M B Fennerty; H S Garewal
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

5.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

Authors:  D J Hetzel; J Dent; W D Reed; F M Narielvala; M Mackinnon; J H McCarthy; B Mitchell; B R Beveridge; B H Laurence; G G Gibson
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

6.  Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus.

Authors:  J E McArdle; K J Lewin; G Randall; W Weinstein
Journal:  Hum Pathol       Date:  1992-05       Impact factor: 3.466

7.  Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy.

Authors:  S Gore; C J Healey; R Sutton; I A Eyre-Brook; M W Gear; N A Shepherd; S P Wilkinson
Journal:  Aliment Pharmacol Ther       Date:  1993-12       Impact factor: 8.171

8.  Esophageal acid sensitivity in Barrett's esophagus.

Authors:  D A Johnson; C Winters; T J Spurling; S J Chobanian; E L Cattau
Journal:  J Clin Gastroenterol       Date:  1987-02       Impact factor: 3.062

9.  Prevalence of metaplasia at the gastro-oesophageal junction.

Authors:  S J Spechler; J M Zeroogian; D A Antonioli; H H Wang; R K Goyal
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

10.  Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD.

Authors:  K C Trimble; A Pryde; R C Heading
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

View more
  8 in total

1.  Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 2.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

3.  Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis.

Authors:  Katie S Nason; Promporn Paula Wichienkuer; Omar Awais; Matthew J Schuchert; James D Luketich; Robert W O'Rourke; John G Hunter; Cynthia D Morris; Blair A Jobe
Journal:  Arch Surg       Date:  2011-07

Review 4.  Esophageal sensitivity and symptom perception in gastroesophageal reflux disease.

Authors:  G Shi; R P Tatum; R J Joehl; P J Kahrilas
Journal:  Curr Gastroenterol Rep       Date:  1999-06

5.  Non-erosive reflux disease (NERD), symptomatic and asymptomatic erosive reflux disease (ERD): from hypersensitive to hyposensitive esophagus.

Authors:  Juanda L Hartono; Choon-Seng Qua; Khean-Lee Goh
Journal:  Dig Dis Sci       Date:  2010-05-14       Impact factor: 3.199

6.  Impairment of secondary peristalsis in Barrett's esophagus by transnasal endoscopy-based testing.

Authors:  Go Kobayashi; Mitsuru Kaise; Hiroshi Arakawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

7.  The pain system in oesophageal disorders: mechanisms, clinical characteristics, and treatment.

Authors:  Christian Lottrup; Søren Schou Olesen; Asbjørn Mohr Drewes
Journal:  Gastroenterol Res Pract       Date:  2011-08-02       Impact factor: 2.260

8.  Esophageal Acid Clearance During Random Swallowing Is Faster in Patients with Barrett's Esophagus Than in Healthy Controls.

Authors:  Christian Lottrup; Anne L Krarup; Hans Gregersen; Per Ejstrud; Asbjørn M Drewes
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.